Senate panel advances $5 million to study ibogaine for traumatic brain injury and PTSD

The Arizona Senate Appropriations Committee voted to give House Bill 2871 a due-pass recommendation after hearing testimony on a proposal to appropriate $5,000,000 from the State General Fund in fiscal year 2026 to the Arizona Department of Health Services (DHS) for phase 1 clinical trials of ibogaine for treatment of traumatic brain injury (TBI), post-traumatic stress disorder (PTSD) and related neurological conditions.

Senator Kyrsten Sinema, presenting the measure as a private citizen and identifying herself as the bill’s original proponent to the sponsor in the House, told the committee the appropriation would seed “phase 1 clinical trials for ibogaine here in Arizona at a world-class neurological institute” and that she had pledged to raise a private $5,000,000 match. Sinema said the funding would begin the FDA approval pathway by supporting safety trials and stressed that initial work must be done in medically supervised settings.

Why it matters: Committee members heard veteran witnesses who described repeated blast exposures and lasting cognitive and mental-health effects they said were not resolved by existing therapies. Supporters argued that early, non‑U.S. studies of ibogaine show promise for reducing cravings in opioid addiction and for marked reductions in PTSD and depressive symptoms; proponents said a successful phase 1 safety study would make it possible to seek additional private and public funds for later-stage trials.

What the bill would do: The measure directs DHS to award competitive grants (an RFP to be issued) to qualified Arizona neurological institutes to conduct phase 1 safety studies required to move an investigational therapy into later FDA trials. The bill text (as described to the committee) limits awards to institutes that meet the statute’s application requirements and exempts the appropriation from lapses.

Committee testimony and technical details: Sinema told the panel that ibogaine is a compound derived from a West African plant and currently listed as a Schedule I substance by the U.S. Drug Enforcement Administration, which limits lawful U.S. access. She described phase 1 trials as safety studies and said subsequent phase 2 and phase 3 work would be required to prove efficacy for particular indications. Sinema and witnesses emphasized that clinical administration requires medical oversight — EKG monitoring and a magnesium IV drip to manage a small cardiac risk — and that the treatment is typically delivered in a supervised clinical setting, sometimes as an outpatient but always with monitoring and integration care afterwards.

Three veterans who had traveled to clinics in Mexico to receive ibogaine spoke to the committee about their experiences. Sergeant First Class Matt Amel (ret.) said the treatment “gave me white space in my brain to start getting healthier” and described an eight‑hour treated experience followed by a week of clinical aftercare. John Soden, an Army veteran who served as a ranger, described the treatment as "the hardest thing I ever had to do" and said it had given him a second chance. Devin Ayuto, who served in naval special warfare support roles, described perceived physical change during the 8–12 hour treatment window and credited a nonprofit scholarship program (identified in testimony as the Vets Foundation) for helping veterans access care in Mexico.

Costs and timelines discussed: Sinema said the House originally proposed $10,000,000 but the amount was amended in the House to $5,000,000 given budget realities; she pledged a $5,000,000 private match. She and other witnesses estimated that completing the full FDA approval process for one indication could require on the order of tens of millions of dollars more (testimony referenced a $50,000,000 figure as a plausible eventual total to reach full approval for multiple indications). Veterans testified that out‑of‑pocket trips to Mexico cost roughly $7,000–$10,000 per participant and included treatment, medical monitoring, and integration care.

Safety and limitations: Committee members pressed on safety, public availability of results and the scope of Arizona’s authority. Sinema said results from an NIH‑style RFP-funded phase 1 study would be publicly reported and that the RFP could include contractual requirements to make findings publicly available; she reiterated that a private sponsor, not the state, would carry later‑stage trials to commercialization. Staff explained DHS would administer the RFP under the state’s grant processes.

Outcome: After questions and public testimony, a senator moved House Bill 2871 with a “due pass” recommendation. The committee recorded a due‑pass recommendation on the bill by a recorded tally of 10 aye, 0 nay. The committee did not take final floor action; the recommendation sends the bill forward in the legislative process.

Ending note: Proponents asked the committee to view Arizona as a place to begin the FDA pathway for a treatment they described as promising for veterans and others with treatment‑resistant conditions; witnesses and some members emphasized the bill’s limited scope to support initial safety testing and placed later commercialization and broader access outside the direct authority of the state.